July 2009
Off-Label Promotion of Drugs and Medical DevicesBy Michael Kendall and Nicole Colby Longton
A spate of billion- and hundred-million-dollar settlements with the Department of Justice (DOJ) illustrates how the investigation of off-label promotions of drugs and devices has emerged as a predominant theory in pharmaceutical and medical-device prosecutions.
Subscribers: click here for the full story
Non-Subscribers: click here to subscribe
Pay per view ($20.00)
